WO2019177374A8 - 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 - Google Patents
2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2019177374A8 WO2019177374A8 PCT/KR2019/002914 KR2019002914W WO2019177374A8 WO 2019177374 A8 WO2019177374 A8 WO 2019177374A8 KR 2019002914 W KR2019002914 W KR 2019002914W WO 2019177374 A8 WO2019177374 A8 WO 2019177374A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- treatment
- inflammatory disease
- prevention
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 상기 화합물은 EGFR(epidermal growth factor receptor) 야생형 또는 돌연변이에 대하여 높은 억제능을 나타내고, JAK3에 대한 억제효과가 우수하므로, EGFR 야생형 또는 EGFR 돌연변이가 발현된 암이나, JAK3의 활성과 관련된 암 또는 염증질환의 치료에 유용하게 사용될 수 있고, 폐암 세포주 증식 억제능이 우수한 바, 특히, 폐암의 치료에 유용하게 사용될 수 있다.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180029416 | 2018-03-13 | ||
KR10-2018-0029416 | 2018-03-13 | ||
KR10-2018-0070252 | 2018-06-19 | ||
KR20180070252 | 2018-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019177374A1 WO2019177374A1 (ko) | 2019-09-19 |
WO2019177374A8 true WO2019177374A8 (ko) | 2020-06-18 |
Family
ID=67906811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/002914 WO2019177374A1 (ko) | 2018-03-13 | 2019-03-13 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20190108080A (ko) |
WO (1) | WO2019177374A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
CN115838369A (zh) | 2019-03-19 | 2023-03-24 | 株式会社沃若诺伊 | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 |
US20240051945A1 (en) * | 2020-10-30 | 2024-02-15 | Blueprint Medicines Corporation | Pyrimidine compounds, compositions, and medicinal applications thereof |
CA3216541A1 (en) * | 2021-04-12 | 2022-10-20 | A2A Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
TW202400575A (zh) | 2022-03-24 | 2024-01-01 | 美商A2A製藥公司 | 治療癌症的組合物和方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
CA2702647C (en) * | 2007-01-31 | 2016-03-22 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
US8450335B2 (en) * | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AU2012250517B2 (en) * | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2015164614A1 (en) * | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2017059280A1 (en) * | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
-
2019
- 2019-03-13 KR KR1020190028954A patent/KR20190108080A/ko not_active Application Discontinuation
- 2019-03-13 WO PCT/KR2019/002914 patent/WO2019177374A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019177374A1 (ko) | 2019-09-19 |
KR20190108080A (ko) | 2019-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019177374A8 (ko) | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 | |
WO2019177375A8 (ko) | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
CR20210415A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2 | |
EP4338802A3 (en) | Tyk2 inhibitors, uses, and methods for production thereof | |
CR20200614A (es) | Compuestos heterocíclicos como inmunomoduladores | |
MX2018002520A (es) | Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo. | |
MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
WO2018155916A3 (ko) | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
MX2017004234A (es) | Inhibidor del egfr y preparacion y aplicacion del mismo. | |
EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
EP3693369A3 (en) | Bromodomain inhibitors | |
IN2014MN02497A (ko) | ||
CN106687454B8 (zh) | 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途 | |
AU2011269989A8 (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
MY149960A (en) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases | |
GEP20227344B (en) | Pyrimidine compound as jak kinase inhibitor | |
AU2018381574A1 (en) | Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor | |
PH12021551268A1 (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
WO2014106800A3 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
WO2016126085A3 (ko) | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 | |
MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
EP3620457A4 (en) | COMPOUND DERIVED FROM PYRIMIDINE, OPTICAL ISOMER, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING A TYRO 3-RELATED DISEASE, CONSIDERING IT AS AN ACTIVE INGREDIENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19767796 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19767796 Country of ref document: EP Kind code of ref document: A1 |